TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~1. Women aged 18 to 70 years old.~2. Has a previous diagnosis of breast cancer (ductal or lobular carcinoma, invasive).~3. 1 year from diagnosis of breast cancer.~4. Stable heterosexual partnership =/\>5 years or by investigator discretion.~5. More than 6 months of consistent insertional pain with intercourse (may have stopped having intercourse due to this consistent experience of pain).~6. Menopausal, demonstrated by at least one of the following:~   i. cessation of menses for 1 years ii. Bilateral oophorectomy iii. Follicle Stimulating Hormone (FSH) level \>25 in women below age 50 with an ovary and scarred or absent uterus (acceptable FSH levels can be inferred if the woman's oncologist monitors FSH during aromatase inhibitor therapy).~7. Willingness to enter a study comparing a topical placebo liquid to topical liquid lidocaine.~8. Willingness to evaluate the liquids by use of a tampon test as many as 4 times per month, and willingness to attempt intercourse if the tampon test indicates tolerable penetrative pain.~3.2 Exclusion Criteria~1. Diagnosis of benign or malignant phyllodes tumor of the breast.~2. Consistently has pain in the pelvis or low abdomen during or after intercourse (deep dyspareunia).~3. Has developed shrinkage of the vaginal opening or vaginal length to the point of being too small to succeed in having vaginal penetration with the partner (will also be assessed at the clinical exam).~4. Partner has a problem of sexual dysfunction limiting his performance or making it inconsistent.~5. The potential subject or her partner has a serious current medical condition that might interrupt completion of a 6 month study.~6. Potential subject has been diagnosed by a physical therapist with significant pelvic floor muscle dysfunction causing pain (pelvic floor myalgia).~7. Potential subject has used topical or systemic estrogen within the last 4 months.~8. Has continued tenderness of vestibule mucosa immediately after application of both test liquids.~9. Allergy to lidocaine or other numbing agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Topical liquid lidocaine (Type: ACTIVE_COMPARATOR): None
- Topical Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults who are between the ages of 18 and 64~Exclusion Criteria:~* Adults who are diagnosed with insomnia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empirical Rescue Therapies of Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* H. pylori -positive patients with functional dyspepsia and scarred peptic ulcers who had previously failed one or more eradication regimens containing clarithromycin, metronidazole and/or amoxicillin.~Exclusion Criteria:~* less than 18 years old, never receiving eradication treatment before, with previous gastric surgery, pregnancy, lactation, major systemic diseases, administration of antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- tetracycline/furazolidone (Type: EXPERIMENTAL): one of the four empirical rescue therapies
- amoxicillin/tetracycline (Type: EXPERIMENTAL): one of the four empirical rescue therapies
- amoxicillin/furazolidone (Type: EXPERIMENTAL): one of the four empirical rescue therapies
- tetracycline /metronidazole (Type: ACTIVE_COMPARATOR): Classical rescue therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior to the run-in period, a history of heartburn or acid regurgitation for 3 months or longer or any history of EE;~* Prior to the run-in period, nighttime heartburn averaging at least 2 or 3 times per week;~* Prior to the run-in period, a history of sleep disturbances associated with GERD for 1 month or more;~Exclusion Criteria:~* Any condition other than GERD that is either the primary cause of, or a significant contributor to, the patient's sleep disturbance~* Sleep medication (including over-the-counter), antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable (either in dose or regularity) for at least 3 months or is not expected to remain stable during the patient's participation in the study. Patients on a stable regimen, whose regimen is also expected to remain stable throughout the study, are eligible for participation;~* Proton Pump Inhibitor (PPI) use within 1 week prior to Screening. The only allowable acid modifying rescue medication is GELUSIL® during the run-in period. Only study medication and rescue medication (GELUSIL®) is allowed during the treatment period for treatment of acid mediated symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nexium 20mg (Type: EXPERIMENTAL): Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages \>18~* Fasting triglyceride ≥200 mg/dL and \<500 mg/dL~* LDL-C (low density lipoprotein - cholesterol) ≥40 mg/dL and \<100 mg/dL~* High risk for coronary heart disease~* On stable dose of statin (atorvastatin, rosuvastatin or simvastatin)~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Women who are pregnant or lactating, or planning to become pregnant~* Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects~* History of bariatric surgery or currently on weight loss drugs~* Uncontrolled hypertension (BP \> 160/100)~* HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin~* Consumption of more than 2 alcoholic beverages per day~* History of cancers (except if been disease free for \>5 years OR history was basal or squamous cell skin cancer)~* Participation in another clinical trial involving an investigational agent in the last 30 days~* Other parameters will be assessed at the study center to ensure eligibility for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AMR101 (ethyl icosapentate) - 2 g/day (Type: EXPERIMENTAL): None
- AMR101 (ethyl icosapentate) - 4 g/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or non-pregnant, non-lactating female subjects Diagnosed with IBS confirmed by the Rome III criteria~Meet the following IBS symptom scores in all categories during the diary eligibility period:~* An average daily score of greater than or equal to 3 for abdominal pain~* An average daily score of greater than or equal to 3 for bloating~* An average daily score of 5 or greater for stool consistency using the Bristol Stool Scale~* Does not have adequate relief of IBS symptoms (weekly reported) over the past 7 days on the first day of screening and on the day of randomization~Exclusion Criteria:~* Present with hard or lumpy stools (Type 1 or Type 2) on the Bristol Stool form Scale during the diary eligibility period~* history of inflammatory bowel disease~* has Type 1 or 2 diabetes~* pregnant or lactating~* history of HIV or hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Mesalamine Granules 750 mg (Type: EXPERIMENTAL): None
- Mesalamine Granules 1500 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Sildenafil Treatment in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* consent to participate in the study after detailed information about procedures, possible clinical benefits and risks;~* negative exercise stress test prior to study initiation;~* forced expiratory volume in 1 sec/forced vital capacity ratio\>70%;~* left ventricular ejection fraction \< 45%, determined by echocardiography.~Exclusion Criteria:~* subjects unable to complete a maximal exercise test~* systolic blood pressure \> 140 and \<110 mmHg~* diabetes mellitus~* therapy with nitrate preparations~* history of sildenafil intolerance~* significant lung or valvular diseases~* neuromuscular disorders, claudication~* peripheral vascular disease

- Gender: MALE
- Minimum Age: 38 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- sildenafil (Type: ACTIVE_COMPARATOR): sildenafil 50 mg three times/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have moderate to severe rheumatoid arthritis~* On methotrexate but inadequately controlled~* Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection~* Subjects must use contraception~Exclusion Criteria:~* Subjects who have been previously treated with adalimumab or Tofacitinib~* Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.~* Subjects with specific laboratory test abnormalities~* Subjects with specific types of infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 5 mg twice daily with methotrexate (Type: EXPERIMENTAL): None
- Tofacitinib 5 mg twice daily monotherapy (Type: EXPERIMENTAL): None
- Adalimumab with methotrexate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with Plasmodium falciparum or P. vivax either alone or mixed~* Age \>12 months~* Weight \>5kg~* Living in the study clusters~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Anaemia, defined as Hb \<9g/dl~* G6PD deficiency (as determined by FST)~* Pregnant women as determined by Urine β-HCG pregnancy test~* Known hypersensitivity to any of the drugs given

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primaquine supervised (Type: ACTIVE_COMPARATOR): 14 days of supervised primaquine treatment (0.5mg/kg/day).
- Primaquine unsupervised (Type: ACTIVE_COMPARATOR): 14 days of unsupervised primaquine treatment (0.5mg/kg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age~2. Genetically confirmed diagnosis of NDMs~3. Participation in the Genetical variability of the Non-dystrophic Myotonia study of J. Trip or a new patient with genetically confirmed NDM.~Exclusion Criteria:~1. Inability or unwillingness to provide informed consent.~2. Other neurological conditions that might affect the assessment of the study measurements.~3. Genetic confirmed Myotonic Dystrophy type 1 (DM1) (CTG \> 50 repeats), or Myotonic Dystrophy type 2 (DM2).~4. Patients with existing cardiac conduction defects, evidenced on ECG including but not limited to the following conditions: malignant arrhythmia or cardiac conduction disturbances (such as second degree AV block, third degree atrio-ventricular (AV) block, or prolonged QT interval \>500 ms or QRS duration \> 150 msec).~5. Current use of the following antiarrhythmic medication for a cardiac disorder:flecainide acetate, encainide, disopyramide, procainamide, quinidine, propafenone or mexiletine.~6. Women who are pregnant or lactating.~7. Patients currently on medications for myotonia such as phenytoin and flecainide acetate within 5 days of enrollment, carbamazepine and mexiletine within 3 days of enrollment, or propafenone, procainamide, disopyramide, quinidine and encainide within 2 days of enrollment.~8. Patients with renal or hepatic disease, heart failure, history of myocardial infarction, or seizure disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets three times daily orally
- Mexiletine (Type: ACTIVE_COMPARATOR): Mexiletine 200mg three times daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female infant between, and including, 6 and 12 weeks of age born after a gestation period of 36 to 42 weeks or a birth weight of \>2000g.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* Planned administration of oral polio vaccine during the period starting from 2 weeks before each dose of study vaccine(s) and ending 2 weeks after.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection~* History of diphtheria, tetanus, pertussis, Hib disease and/ or hepatitis B.~* Previous vaccination against diphtheria, tetanus, pertussis, and/or Haemophilus influenzae type b.~* History of allergic disease~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.~* Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination)~* Previous confirmed occurrence of RV GE.~* Household contact with an immunosuppressed individual or pregnant women.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Initial Management of the Injured at Ghanaian District and Regional Hospitals With a Trauma Intake Form

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency health care providers at the study hospitals~* Patient with injury who is treated in the emergency unit of one of the study hospitals~Exclusion Criteria:~* Non-emergency health care providers at the study hospitals~* Non-injured patient at the study hospitals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre TIF introduction (Type: NO_INTERVENTION): Emergency Health Service prior to introduction of TIF.
- Post introduction of TIF (Type: EXPERIMENTAL): Emergency Health Service after introduction of TIF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a first-time recipient of a kidney transplant from a deceased donor.~* Specific donor criteria~Exclusion Criteria:~* Donor age \<10 years~* Subjects receiving a concurrent solid organ or cell transplant (lung, heart, etc.)~* Subjects with a positive T-cell lymphocytotoxic crossmatch.~* Subjects who are positive for Hepatitis B or C, or HIV~* Active tuberculosis~* History of cancer in the last 5 years~* History of substance abuse~* Specific laboratory results are exclusionary~* Mammography suspicious for cancer~* Allergy to iodine~* For Long-term extension study-Subjects who have completed three years of study treatment (through Week 156)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporin A (Type: ACTIVE_COMPARATOR): None
- Belatacept Less Intensive Regimen (LI) (Type: EXPERIMENTAL): None
- Belatacept More Intensive Regimen (MI) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Maternal age: 18-35 years old (to decrease the incidence of preterm labor related to age factor).~2. Women who present with viable pregnancy (between 28 and 37 weeks' gestation), and having a threatened preterm labor (which is defined as ≥ 2 uterine contractions at 28-37 weeks' gestation, The onset of labor may be determined by documented uterine contractions (at least one every 10 minutes) and ruptured fetal membranes or documented cervical change with an estimated length of less than 1cm or cervical dilation of more than 2 cm. Threatened preterm labor may be diagnosed when there are documented uterine contractions but no evidence of cervical change.~Exclusion Criteria:~1. Multiple pregnancy.~2. Documented uterine anomalies.~3. Oligohydramnios and polyhydramnios .~4. Medical disorders as Diabetes mellitus and hypertension.~5. Preterm premature rupture of membranes.~6. Conditions that may have an influence on immune reaction e.g. history of chorioamnionitis.~7. Smoking as a risk factor for preterm labor.~8. Patients having Autoimmune disorder as it may affect Uterine NK( natural killer ) cells level .

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Preterm labor (Type: None): Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
- Term labor (Type: None): Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete